Genito Urinary System And Sex Hormones

SeaStar’s device granted humanitarian exemption approval for children with AKI

Following positive clinical results, the US Food Drug Administration (FDA) has granted SeaStar Medical a humanitarian device exemption (HDE) approval…

Travere signs $120m licencing deal with Renalys for sparsentan in Asia

Travere Therapeutics has signed a licencing agreement for sparsentan with Japan-based Renalys Pharma for multiple Asian countries. As per the…

Vera’s Phase IIb OLE trial gives extra confidence for Phase III IgAN trial

Vera Therapeutics has said that Phase II open-label expansion (OLE) study data gives extra confidence in the ongoing Phase III…

UroMems hits trial success for automated urinary sphincter implant

UroMems has reached another checkpoint in bringing the first automated artificial urinary sphincter to market after the company announced its…

Calliditas starts Phase II trial for rare kidney disease therapy

Calliditas Therapeutics has initiated a Phase II trial to evaluate setanaxib as a treatment for Alport syndrome. The randomised, placebo-controlled…

Pipeline Moves: Approval prospects rise for oesophageal cancer drug after trial completion

This week on Pipeline Moves, we kickoff by looking at the completion of a Phase III trial in oesophageal cancer.…

Novartis’ atrasentan shows superiority in Phase III IgAN trial

Novartis has reported positive topline data from an ongoing Phase III trial investigating atrasentan in patients with IgA nephropathy (IgAN).…

Omeros’ narsoplimab fails Phase III kidney disease trial

Omeros Coroporation’s narsoplimab has failed to produce positive results in an interim analysis of a Phase III trial investigating its…

Novartis eyes accelerated FDA approval for iptacopan across multiple indications

Novartis has announced positive interim results for iptacopan from the Phase III Applause-IgAN study showing significant proteinuria reduction in patients…

UroMems completes device implants for stress urinary incontinence trial

UroMems has completed enrolment in a clinical study investigating its automated artificial urinary sphincter to treat stress urinary incontinence (SUI).…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close